- Home
- REX vs VOR Comparison
REX vs VOR Comparison
Compare REX & VOR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | REX | VOR |
|---|---|---|
| Founded | 1980 | 2015 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Major Chemicals | Biotechnology: Pharmaceutical Preparations |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.4B | 1.4B |
| IPO Year | 1994 | 2021 |
Fundamental Metrics
Financial Performance| Metric | REX | VOR |
|---|---|---|
| Price | $41.46 | $25.05 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 10 |
| Target Price | N/A | ★ $45.33 |
| AVG Volume (30 Days) | 134.0K | ★ 695.4K |
| Earning Date | 05-27-2026 | 05-11-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ 1.62 | N/A |
| Revenue | ★ $650,487,000.00 | N/A |
| Revenue This Year | $19.45 | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $73.64 | ★ N/A |
| Revenue Growth | ★ 1.24 | N/A |
| 52 Week Low | $30.02 | $6.50 |
| 52 Week High | $53.36 | $49.95 |
Technical Indicators
Market Signals| Indicator | REX | VOR |
|---|---|---|
| Relative Strength Index (RSI) | 41.28 | 59.34 |
| Support Level | $32.04 | $21.83 |
| Resistance Level | $41.79 | $24.44 |
| Average True Range (ATR) | 1.64 | 1.01 |
| MACD | -0.10 | -0.11 |
| Stochastic Oscillator | 26.76 | 71.22 |
Price Performance
Historical ComparisonAbout REX REX American Resources Corporation
REX American Resources Corp operates as a holding company that engages in investments in alternative energy and ethanol production entities. Its operating segments include Ethanol and By-Products. Its products include Ethanol, dried distillers grains, modified distillers grains, Distillers corn oil, Modified distillers grains, and Other.
About VOR Vor Biopharma Inc.
Vor Biopharma Inc is a clinical-stage biopharmaceutical company focused on developing novel therapies for the treatment of autoimmune diseases. Its program, telitacicept, is a potential first- and best-in-class dual BAFF/APRIL inhibitor designed to suppress the signaling pathways that drive the maturation, proliferation, and survival of harmful B cells, including self-reactive B cells, thereby reducing autoantibody production and preventing downstream tissue damage.